Canadian Cancer Society logo

Childhood Hodgkin lymphoma

You are here: 

Survival statistics for childhood Hodgkin lymphoma

Survival statistics for childhood Hodgkin lymphoma (HL) are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of children, they can’t be used to predict a particular child’s chances of survival.

There are many different ways to measure and report cancer survival statistics. Your child’s doctor can explain the statistics for childhood HL and what they mean for your child.

Observed survival

Sometimes an observed survival is reported for childhood HL. This observed survival rate is often used when talking about prognosis. Observed survival is the proportion of children and youth with the same cancer who are alive at a given period of time after their diagnosis. Observed survival does not consider the cause of death, so children could have died from cancer or from other causes.

The 5-year observed survival for Hodgkin lymphoma in children 0–14 years of age is 98%. This means that, on average, 98% of children diagnosed with Hodgkin lymphoma are expected to be alive 5 years after their diagnosis.

Classic childhood HL is divided into risk groups based on stage, bulk of the tumour and symptoms. Treatment options are based on these risk groups. There are no specific Canadian survival statistics available for the different risk groups of HL in children and youth.

Questions about survival

Parents of children with cancer should talk to their child’s doctor about the prognosis. Prognosis depends on many factors, including:

  • a child’s medical history
  • type of cancer
  • stage
  • characteristics of the cancer
  • treatments chosen
  • response to treatment

Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.


Stephanie Hermsen Thanks to the incredible progress in retinoblastoma research made possible by Canadian Cancer Society funding, my son won’t have to go through what I did.

Read Stephanie's story

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more